|
|
Article: Neurocrine Biosciences Announces U.S. Issuance of Composition of Matter Patent for Its Phase III Insomnia Compound; 18 Years of Patent Exclusivity of Indiplon (NBI-34060).
- Article from:
- PR Newswire
- Article date:
- June 4, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Indiplon Is the New Development Name for NBI-34060
SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. announced today the issuance of U.S. Patent No. 6,399,621 (the '621 patent) covering the chemical composition of its proprietary compound indiplon (NBI-34060) for the treatment of insomnia. The '621 patent will provide Neurocrine with patent exclusivity for indiplon to the year 2020 and has greatly enhanced the value of this very important asset. By comparison, at the time of marketing approval most drugs only have 8-10 years of patent life remaining. Neurocrine is currently conducting one of the largest and the most comprehensive ...